Malaria Vaccine Agreements
May 13 2009 - 2:00AM
UK Regulatory
TIDMLPX
RNS Number : 1447S
Lipoxen PLC
13 May 2009
+--------------------------------------+--------------------------------------+
| For immediate release | 13 May 2009 |
+--------------------------------------+--------------------------------------+
Lipoxen PLC
('Lipoxen' or 'the Company')
Agreements with the PATH Malaria Vaccine Initiative and US NIAID
Preclinical feasibility project to determine ability of Lipoxen's
Liposomal
Technology to stimulate enhanced immune responses against malaria
protein
Lipoxen PLC (AIM: LPX), a bio-pharmaceutical company specialising in the
development of high-value differentiated biologicals, vaccines and siRNA
delivery, announces today that the Company has received funding to apply its
ground-breaking ImuXen technology to enhance the performance of malaria vaccine
candidates. The PATH Malaria Vaccine Initiative, a program of the non-profit
organization, PATH, will provide funding for the project. Scientists from the US
National Institute of Allergy and Infectious Diseases (NIAID), a component of
the US National Institutes of Health, will provide expertise to the project,
which is anticipated to report results in mid-2010.
The project will apply Lipoxen's patented technology with a view to improving
the ultimate performance and efficacy of malaria vaccines. Lipoxen will be
responsible for the development of an optimised malaria vaccine formulation,
while NIAID scientists will be responsible for evaluating its activity in a
relevant pre-clinical model.
Lipoxen's proprietary ImuXen technology is based on the use of natural
substances found in the human body (liposomes) to entrap the active ingredients
(a malaria antigen in this project) to ensure their direct delivery to the
appropriate cells of the immune system, thereby enhancing the effectiveness of
vaccines by generating strong and broadly based immune responses. The resulting
immune responses are expected to be much stronger and more rapid than with
vaccines delivered by conventional means. The Company's liposomal formulations
are also expected to minimise the side effects of vaccination as a result of the
containment and slow release of the active materials.
Commenting on this announcement, M. Scott Maguire, CEO of Lipoxen, said:
"The scourge that is malaria causes a death every 30 seconds in Africa alone.
With funding from PATH we will explore whether our technology is suitable for
malaria vaccines. The decision by NIAID, a world-leading biomedical research
organization, to participate in this project will unquestionably accelerate this
exploration.
"Lipoxen has other globally important vaccine candidates in its pipeline -
including one against HIV. 2.1 million deaths in 2007 were attributed to HIV
infection; this equates to 4 deaths per minute. The Company is also working
alongside the International AIDS Vaccine Initiative (IAVI), the world's leading
AIDS vaccine organization, on the improved delivery of HIV vaccine candidates.
This is yet another externally funded research project with considerable
potential to alleviate suffering in the developing world and beyond. We also
have a novel influenza vaccine candidate in development that has recently
produced positive results in preclinical studies.
"Our Company is rapidly building a reputation in the field of novel vaccine
development and delivery and each of these projects demonstrate Lipoxen's desire
and commitment to help solve some of the gravest problems afflicting humanity."
- Ends -
For further information please contact:
+-------------------------------------------------+-------------------------+
| Lipoxen plc | +44 (0)20 7691 3583 |
+-------------------------------------------------+-------------------------+
| M. Scott Maguire, Chief Executive Officer | |
+-------------------------------------------------+-------------------------+
| | |
+-------------------------------------------------+-------------------------+
| Singer Capital Markets (nominated adviser) | +44 (0)20 3205 7500 |
+-------------------------------------------------+-------------------------+
| Jeff Keating / Claes Spång | |
+-------------------------------------------------+-------------------------+
| | |
+-------------------------------------------------+-------------------------+
| Noble & Company | +44 (0) 20 7763 2200 |
+-------------------------------------------------+-------------------------+
| John Llewellyn-Lloyd / Sam Reynolds | |
+-------------------------------------------------+-------------------------+
| | |
+-------------------------------------------------+-------------------------+
| Buchanan Communications | +44 (0)20 7466 5000 |
+-------------------------------------------------+-------------------------+
| Mary-Jane Elliott, Lisa Baderoon, Rebecca Skye | |
| Dietrich, Catherine Breen | |
+-------------------------------------------------+-------------------------+
Notes for Editors
Lipoxen
About Lipoxen
Lipoxen plc is a biopharmaceutical company focused on the development of new and
improved biologic drugs and vaccines. Lipoxen has three proprietary patented
technology platforms:
1. PolyXen - for extending the efficacy and half life of biologic drugs
2. ImuXen - for creating new vaccines and improving existing vaccines
3. SiRNAblate - for the delivery of siRNA
Lipoxen's technology is designed to improve the efficacy, safety, stability,
biological half-life and immunologic characteristics of its products.
Lipoxen has multiple drug and vaccine programmes in development. Two products
are in clinical development, SuliXen, a long acting insulin and ErepoXen, a
long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes Factor
XIII and vaccines against HIV, influenza and malaria.
The Company has a low-risk business model and out-licenses its proprietary
technologies to biopharmaceutical companies that have strong manufacturing and
marketing capabilities. Lipoxen currently has commercial agreements with some of
the world's leading biotechnology and pharmaceutical companies including Baxter,
Schering-Plough, Sanofi-Aventis, the Serum Institute of India Limited,
Genentech, Amgen and Genzyme.
Lipoxen, which was founded in 1997, now trades on the AIM Market of the London
Stock Exchange under the ticker symbol LPX. More information can be found at the
Company's website: www.lipoxen.com.
On the Internet:
PATH Malaria Vaccine Initiative, www.malariavaccine.org
PATH, www.path.org
This announcement includes 'forward-looking statements' which include all
statements other than statements of historical facts, including, without
limitation, those regarding the Company's financial position, business strategy,
plans and objectives of management for future operations (including development
plans and objectives relating to the Company's products and services), and any
statements preceded by, followed by or that include forward-looking terminology
such as the words 'targets', 'believes', 'estimates', 'expects', 'aims',
'intends', 'will', 'can', 'may', 'anticipates', 'would', 'should', 'could' or
similar expressions or the negative thereof. Such forward-looking statements
involve known and unknown risks, uncertainties and other important factors
beyond the Company's control that could cause the actual results, performance or
achievements of the Company to be materially different from future results,
performance or achievements expressed or implied by such forward-looking
statements. Such forward-looking statements are based on numerous assumptions
regarding the Company's present and future business strategies and the
environment in which the Company will operate in the future. Among the important
factors that could cause the Company's actual results, performance or
achievements to differ materially from those in forward-looking statements
include those relating to The Company's funding requirements, regulatory
approvals, clinical trials, reliance on third parties, intellectual property,
key personnel and other factors. These forward-looking statements speak only as
at the date of this announcement. The Company expressly disclaims any obligation
or undertaking to disseminate any updates or revisions to any forward-looking
statements contained in this announcement to reflect any change in the Company's
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statements are based. As a result of these
factors, readers are cautioned not to rely on any forward-looking statement.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCZGGMKZZLGLZZ
Lipoxen (LSE:LPX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lipoxen (LSE:LPX)
Historical Stock Chart
From Jul 2023 to Jul 2024
